Reactie op de consultatie van de Europese Commissie over het vergoedingensysteem van het Europees Geneesmiddelenagentschap (EMA).
Dit document is in het Engels.
Ook interessant voor je
European Commission approves potential new treatment for Pompe disease
The European Commission (EC) has issued a marketing authorisation for Sanofi Genzyme’s therapy Nexviadyme (avalglucosidase alfa) for the long-term treatment of both late-onset and infantile-onset Pompe disease. Pompe...
4 x gelezen
AbbVie submits migraine prevention drug to EMA for marketing authorisation
AbbVie has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for atogepant as a migraine treatment for adults who have at least four migraine days per month. Atogepant is an...
1 x gelezen
Mixed Results for Paxlovid in Standard Risk Patients With COVID-19
Additional findings were announced from a phase 2/3 study evaluating the efficacy and safety of Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) in patients with COVID-19 who are at standard risk of...